efgartigimod administration clinical trials

Efgartigimod in IVIG Dependent Myasthenia Gravis Patients

This study looks at a new drug, efgartigimod, as a potential replacement for IVIG treatment in people with myasthenia gravis. Researchers want to see if it works as well as IVIG and is safe. Patients will receive efgartigimod infusions over 26 weeks.